Posted in | News | Gold | Mining Business

Platinex Receives Approval to Expand Shining Tree Gold Property

Platinex Inc. ("Platinex" or the "Company") has received the TSX Venture Exchange's approval to complete the transaction described in the Company's press release dated November 3, 2016 to expand the Shining Tree gold property and has issued an aggregate of 398,000 common shares of Platinex (the "Issued Securities").

The recent Shining Tree gold property acquisitions have increased the project size to 286 claim units (4,576 ha or 11,440 acres). The Shining Tree gold property covers many historic workings, and gold showings within an underexplored area. All weather logging roads provide year round access.

The Issued Securities carry a four-month hold period under Canadian securities laws from the date of issuance.

About Platinex Inc.

Platinex's goal is to create shareholder value through exploration, opportunistic acquisition and discovery of commercial deposits with a focus on gold. Platinex has revealed strong evidence of a major gold bearing zone on its Shining Tree property as evidenced by a provincially significant, extraordinarily high gold content of soil samples (glacial till) along a nine km long corridor. Shares of Platinex are listed for trading on the TSX Venture Exchange under the symbol "PTX".

The information presented in this news release has been reviewed and approved by James R. Trusler, Geological Engineer, the Chief Executive Officer of the Company and the Qualified Person for exploration at the Shining Tree property, as defined by National Instrument 43-101 "Standards of Disclosure for Mineral Projects".

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.